You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCilazapril
Accession NumberDB01340
TypeSmall Molecule
GroupsApproved
Description

Cilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure. It belongs to the angiotensin-converting enzyme inhibitors (ACE inhibitors) class of drugs. It is a prodrug that is hydrolyzed after absorption to its main metabolite cilazaprilat. It is branded as Inhibace in Canada and other countries, Vascace and Dynorm in a number of European countries, among many other names. None of these varieties are available in the United States.

Structure
Thumb
Synonyms
Cilazapril
Cilazaprilum
External Identifiers
  • Ro 31-2848
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cilazapriltablet5 mgoralSanis Health Inc2010-05-312014-08-01Canada
Cilazapriltablet5.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cilazapriltablet2.5 mgoralSanis Health Inc2010-05-31Not applicableCanada
Cilazapriltablet2.5 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Cilazapriltablet1 mgoralSanis Health Inc2010-05-31Not applicableCanada
Cilazapriltablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Cilazapriltablet1.0 mgoralCobalt Pharmaceuticals CompanyNot applicableNot applicableCanada
Co Cilazapriltablet2.5 mgoralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Co Cilazapriltablet5.0 mgoralCobalt Pharmaceuticals Company2007-02-06Not applicableCanada
Dom-cilazapriltablet5.0 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazapriltablet2.5 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-cilazapriltablet1.0 mgoralDominion PharmacalNot applicableNot applicableCanada
Inhibace Tab 1mgtablet1 mgoralHoffmann La Roche Limited1993-12-312010-07-21Canada
Inhibace Tab 2.5mgtablet2.5 mgoralHoffmann La Roche Limited1993-12-31Not applicableCanada
Inhibace Tab 5mgtablet5 mgoralHoffmann La Roche Limited1993-12-31Not applicableCanada
Mylan-cilazapriltablet5.0 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazapriltablet2.5 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Mylan-cilazapriltablet1 mgoralMylan Pharmaceuticals Ulc2006-07-21Not applicableCanada
Ntp-cilazapriltablet5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazapriltablet2.5 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ntp-cilazapriltablet1 mgoralTeva Canada LimitedNot applicableNot applicableCanada
PHL-cilazapriltablet5.0 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazapriltablet2.5 mgoralPharmel Inc2008-10-30Not applicableCanada
PHL-cilazapriltablet1.0 mgoralPharmel Inc2008-10-30Not applicableCanada
PMS-cilazapriltablet5.0 mgoralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazapriltablet2.5 mgoralPharmascience Inc2006-06-09Not applicableCanada
PMS-cilazapriltablet1.0 mgoralPharmascience Inc2006-06-09Not applicableCanada
Teva-cilazapriltablet2.5 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazapriltablet1 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Teva-cilazapriltablet5 mgoralTeva Canada Limited2005-04-01Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cilazapriltablet1 mgoralApotex Inc2007-02-01Not applicableCanada
Apo-cilazapriltablet5 mgoralApotex Inc2007-02-01Not applicableCanada
Apo-cilazapriltablet2.5 mgoralApotex Inc2007-02-01Not applicableCanada
Over the Counter ProductsNot Available
International Brands
NameCompany
DynormRoche
InhibaceRoche
InhibestrilTeva
VascaceRoche
ZaprilMylan
ZoboxHemofarm
Brand mixtures
NameLabellerIngredients
Apo-cilazapril/hctzApotex Inc
Inhibace Plus - TabHoffmann La Roche Limited
Novo-cilazapril/hctzTeva Canada Limited
Salts
Name/CASStructureProperties
Cilazapril Hydrate
ThumbNot applicableDBSALT001097
Categories
UNII19KW7PI29F
CAS number92077-78-6
WeightAverage: 417.4986
Monoisotopic: 417.226371117
Chemical FormulaC22H31N3O5
InChI KeyInChIKey=HHHKFGXWKKUNCY-FHWLQOOXSA-N
InChI
InChI=1S/C22H31N3O5/c1-2-30-22(29)18(13-12-16-8-4-3-5-9-16)23-17-10-6-14-24-15-7-11-19(21(27)28)25(24)20(17)26/h3-5,8-9,17-19,23H,2,6-7,10-15H2,1H3,(H,27,28)/t17-,18-,19-/m0/s1
IUPAC Name
(1S,9S)-9-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-10-oxo-octahydro-1H-pyridazino[1,2-a][1,2]diazepine-1-carboxylic acid
SMILES
CCOC(=O)[[email protected]](CCC1=CC=CC=C1)N[[email protected]]1CCCN2CCC[[email protected]](N2C1=O)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acid esters
Alternative Parents
Substituents
  • Alpha-amino acid ester
  • Phenylpropylamine
  • Aralkylamine
  • Fatty acid ester
  • Diazepane
  • 1,2-diazepane
  • Fatty acyl
  • Benzenoid
  • Pyridazine
  • Dicarboxylic acid or derivatives
  • 1,2-diazinane
  • Monocyclic benzene moiety
  • Carboxylic acid hydrazide
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationCilazapril is an ACE inhibtor class drug used in the treatment of hypertension and heart failure.
PharmacodynamicsCilazapril inhibits the production angiotensin II. By doing so, it decreases sodium and water reabsorption (via aldosterone) and it decreases vasoconstriction. The combined effect of this is a decrease in vascular resistance, and therefore, blood pressure. The absolute bioavailability of cilazaprilat after oral administration of cilazapril is 57% based on urinary recovery data. (The absolute bioavailability of cilazaprilat after oral administration of cilazaprilat is 19%.) Ingestion of food immediately before the administration of cilazapril reduces the average peak plasma concentration of cilazaprilat by 29%, delays the peak by one hour and reduces the bioavailability of cilazaprilat by 14%. These pharmacokinetic changes have little influence on plasma ACE inhibition.
Mechanism of actionCilazapril is a pyridazine ACE inhibitor. It competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. As angiotensin II is a vasoconstrictor and a negative feedback mediator for renin activity, lower angiotensin II levels results in a decrease in blood pressure, an increase in renin activity, and stimulation of baroreceptor reflex mechanisms. Kininase II, an enzyme which degrades the vasodilator bradykinin, is identical to ACE and may also be inhibited.
Related Articles
AbsorptionMaximum plasma concentrations of cilazaprilat are reached within two hours after administration of cilazapril.
Volume of distributionNot Available
Protein bindingMaximum ACE inhibition is greater than 90% after 1 to 5 mg cilazapril. Maximum ACE inhibition is 70 to 80% after 0.5 mg cilazapril. Dose proportionality is observed following the administration of 1 to 5 mg cilazapril. Apparent non-proportionality is observed at 0.5 mg reflective of the binding to ACE. The higher doses of cilazapril are associated with longer duration of maximum ACE inhibition.
Metabolism
SubstrateEnzymesProduct
Cilazapril
Not Available
CilazaprilatDetails
Route of eliminationCilazaprilat is eliminated unchanged by the kidneys. The total urinary recovery of cilazaprilat after intravenous administration of 2.5 mg is 91%.
Half lifeHalf-lives for the periods 1 to 4 hours and 1 to 7 days after the intravenous administration of 2.5 mg cilazaprilat are 0.90 and 46.2 hours respectively.
Clearance

Total clearance is 12.3 L/h and renal clearance is 10.8 L/h. The total urinary recovery of cilazaprilat following the oral administration of 2.5 mg cilazapril is 52.6%.

ToxicityLimited data are available with regard to overdosage in humans. The most likely manifestations are hypotension, which may be severe, hyperkalaemia, hyponatraemia and renal impairment with metabolic acidosis. Treatment should be mainly symptomatic and supportive.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Cilazapril Metabolism PathwayDrug metabolismSMP00592
Cilazapril Action PathwayDrug actionSMP00147
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9157
Blood Brain Barrier-0.9402
Caco-2 permeable-0.7698
P-glycoprotein substrateSubstrate0.8727
P-glycoprotein inhibitor IInhibitor0.7775
P-glycoprotein inhibitor IINon-inhibitor0.8788
Renal organic cation transporterNon-inhibitor0.8318
CYP450 2C9 substrateNon-substrate0.7876
CYP450 2D6 substrateNon-substrate0.8283
CYP450 3A4 substrateSubstrate0.5396
CYP450 1A2 substrateNon-inhibitor0.882
CYP450 2C9 inhibitorNon-inhibitor0.7804
CYP450 2D6 inhibitorNon-inhibitor0.7503
CYP450 2C19 inhibitorNon-inhibitor0.816
CYP450 3A4 inhibitorNon-inhibitor0.8201
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8376
Ames testNon AMES toxic0.6023
CarcinogenicityNon-carcinogens0.9028
BiodegradationNot ready biodegradable0.9942
Rat acute toxicity2.3700 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9311
hERG inhibition (predictor II)Inhibitor0.6303
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tabletoral
Tabletoral2.5 mg
Tabletoral5 mg
Tabletoral1 mg
Tabletoral1.0 mg
Tabletoral5.0 mg
Prices
Unit descriptionCostUnit
Inhibace 5 mg Tablet0.94USD tablet
Inhibace 2.5 mg Tablet0.81USD tablet
Inhibace 1 mg Tablet0.7USD tablet
Apo-Cilazapril 5 mg Tablet0.52USD tablet
Co Cilazapril 5 mg Tablet0.52USD tablet
Mylan-Cilazapril 5 mg Tablet0.52USD tablet
Novo-Cilazapril 5 mg Tablet0.52USD tablet
Pms-Cilazapril 5 mg Tablet0.52USD tablet
Apo-Cilazapril 2.5 mg Tablet0.45USD tablet
Co Cilazapril 2.5 mg Tablet0.45USD tablet
Mylan-Cilazapril 2.5 mg Tablet0.45USD tablet
Novo-Cilazapril 2.5 mg Tablet0.45USD tablet
Pms-Cilazapril 2.5 mg Tablet0.45USD tablet
Apo-Cilazapril 1 mg Tablet0.39USD tablet
Mylan-Cilazapril 1 mg Tablet0.39USD tablet
Novo-Cilazapril 1 mg Tablet0.39USD tablet
Pms-Cilazapril 1 mg Tablet0.39USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20060293517 No2004-03-082024-03-08Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point98 ºC with decomposition Not Available
water solubilityWater (25 ºC) 0.5 g/100 mL Not Available
logP0.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.06 mg/mLALOGPS
logP-0.2ALOGPS
logP-0.0079ChemAxon
logS-2.6ALOGPS
pKa (Strongest Acidic)3.41ChemAxon
pKa (Strongest Basic)5.35ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area99.18 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity110.56 m3·mol-1ChemAxon
Polarizability44.73 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Attwood, M. R.; Hassall, C. H.; Kr�Hn, A.; Lawton, G.; Redshaw, S. (1986). “The design and synthesis of the Angiotensin Converting Enzyme inhibitor Cilazapril and related bicyclic compounds”. Journal of the Chemical Society, Perkin Transactions 1: 1011. doi:10.1039/P19860001011

US20060293517
General References
  1. Fasanella d'Amore T, Bussien JP, Nussberger J, Waeber B, Turini GA, Brunner HR, Kler L, Francis RJ: Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers. J Cardiovasc Pharmacol. 1987 Jan;9(1):26-31. [PubMed:2434790 ]
External Links
ATC CodesC09AA08C09BA08
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelDownload (114 KB)
MSDSDownload (81.5 KB)
Interactions
Drug Interactions
Drug
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Cilazapril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Cilazapril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Cilazapril.
AliskirenAliskiren may increase the hyperkalemic activities of Cilazapril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazapril.
AmifostineCilazapril may increase the hypotensive activities of Amifostine.
AprotininAprotinin may decrease the antihypertensive activities of Cilazapril.
ArdeparinArdeparin may increase the hyperkalemic activities of Cilazapril.
AzathioprineCilazapril may increase the myelosuppressive activities of Azathioprine.
BrimonidineBrimonidine may increase the antihypertensive activities of Cilazapril.
ButabarbitalButabarbital may increase the hypotensive activities of Cilazapril.
ButethalButethal may increase the hypotensive activities of Cilazapril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Cilazapril.
CiprofloxacinCilazapril may increase the arrhythmogenic activities of Ciprofloxacin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.
DiazoxideDiazoxide may increase the hypotensive activities of Cilazapril.
DrospirenoneCilazapril may increase the hyperkalemic activities of Drospirenone.
DuloxetineCilazapril may increase the orthostatic hypotensive activities of Duloxetine.
EplerenoneEplerenone may increase the hyperkalemic activities of Cilazapril.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Cilazapril.
HeparinHeparin may increase the hyperkalemic activities of Cilazapril.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Cilazapril.
HexobarbitalHexobarbital may increase the hypotensive activities of Cilazapril.
IcatibantIcatibant may decrease the antihypertensive activities of Cilazapril.
InfliximabThe risk or severity of adverse effects can be increased when Cilazapril is combined with Infliximab.
IronThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Cilazapril is combined with Iron Dextran.
LanthanumThe serum concentration of Cilazapril can be decreased when it is combined with Lanthanum.
LevodopaCilazapril may increase the orthostatic hypotensive activities of Levodopa.
LithiumThe serum concentration of Lithium can be increased when it is combined with Cilazapril.
MethohexitalMethohexital may increase the hypotensive activities of Cilazapril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Cilazapril.
MolsidomineMolsidomine may increase the hypotensive activities of Cilazapril.
MoxonidineMoxonidine may increase the hypotensive activities of Cilazapril.
NicorandilNicorandil may increase the hypotensive activities of Cilazapril.
ObinutuzumabCilazapril may increase the hypotensive activities of Obinutuzumab.
PentobarbitalPentobarbital may increase the hypotensive activities of Cilazapril.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Cilazapril.
PhenelzinePhenelzine may increase the orthostatic hypotensive activities of Cilazapril.
PregabalinThe risk or severity of adverse effects can be increased when Cilazapril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Cilazapril.
QuinineQuinine may increase the hypotensive activities of Cilazapril.
RisperidoneCilazapril may increase the hypotensive activities of Risperidone.
RituximabCilazapril may increase the hypotensive activities of Rituximab.
SacubitrilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sacubitril.
SecobarbitalSecobarbital may increase the hypotensive activities of Cilazapril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazapril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Cilazapril.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sodium aurothiomalate.
TadalafilTadalafil may increase the antihypertensive activities of Cilazapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Cilazapril.
TizanidineTizanidine may increase the hypotensive activities of Cilazapril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Cilazapril.
TorasemideTorasemide may increase the hypotensive activities of Cilazapril.
TranylcypromineTranylcypromine may increase the orthostatic hypotensive activities of Cilazapril.
TreprostinilTreprostinil may increase the hypotensive activities of Cilazapril.
TriamtereneTriamterene may increase the hyperkalemic activities of Cilazapril.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Cilazapril.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Cilazapril.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Cilazapril.
VardenafilVardenafil may increase the antihypertensive activities of Cilazapril.
YohimbineYohimbine may decrease the antihypertensive activities of Cilazapril.
Food Interactions
  • Food decreases cilazapril absorption with no significant clinical impact.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Yoshiyama M, Takeuchi K, Omura T, Kim S, Yamagishi H, Toda I, Teragaki M, Akioka K, Iwao H, Yoshikawa J: Effects of candesartan and cilazapril on rats with myocardial infarction assessed by echocardiography. Hypertension. 1999 Apr;33(4):961-8. [PubMed:10205231 ]
  2. Kihara M, Mitsui MK, Mitsui Y, Okuda K, Nakasaka Y, Takahashi M, Schmelzer JD: Altered vasoreactivity to angiotensin II in experimental diabetic neuropathy: role of nitric oxide. Muscle Nerve. 1999 Jul;22(7):920-5. [PubMed:10398211 ]
  3. Mervaala E, Dehmel B, Gross V, Lippoldt A, Bohlender J, Milia AF, Ganten D, Luft FC: Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes. J Am Soc Nephrol. 1999 Aug;10(8):1669-80. [PubMed:10446934 ]
  4. Rosendorff C, Patton J, Radford HM, Kalliatakis B: Alpha-adrenergic and angiotensin II pressor sensitivity in hypertensive patients treated with an angiotensin-converting enzyme inhibitor. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S105-9. [PubMed:1382157 ]
  5. Hannedouche T, Ikeni A, Marques LP, Natov S, Dechaux M, Schmitt F, Lacour B, Grunfeld JP: Renal effects of angiotensin II in normotensive subjects on short-term cilazapril treatment. J Cardiovasc Pharmacol. 1992;19 Suppl 6:S25-7. [PubMed:1382161 ]
  6. Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B: Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008 Sep;52(3):486-93. doi: 10.1053/j.ajkd.2008.02.297. Epub 2008 Apr 18. [PubMed:18423812 ]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 30, 2007 12:09 / Updated on December 05, 2014 11:49